PBM Rules Are Pivotal Point Of Medicare Rx Debate, Breaux Tells PhRMA

The structure of competition among PBMs is a key point for industry to weigh in on during the Medicare drug benefit debate, Sen. Breaux (D-La.) told the Pharmaceutical Research & Manufacturers of America annual meeting March 31 in Naples, Fla.